Document:

Exhibit 10.8(d)

 

THIRD AMENDMENT TO

THE DISTRIBUTION AGREEMENT 

BY AND BETWEEN

DYAX CORP.

AND

WALGREENS INFUSION SERVICES, INC.

 

THIS THIRD AMENDMENT TO THE DISTRIBUTION
AGREEMENT  (the “Amendment”) is made and entered into as of this 30th day of December, 2014, by and between DYAX
CORP., a Delaware corporation (“Dyax”), and WALGREENS INFUSION SERVICES, INC., a Delaware corporation (“Walgreens”),
to amend that certain Agreement For Services Related to Kalbitor, effective as of September 1, 2011, entered into by and between
Dyax and Walgreens, as modified by the First Amendment dated as of August 31, 2012, and the Second Amendment dated January 1, 2014
(collectively the “Agreement”). Capitalized terms used herein which are not defined shall have the meanings given to
them in the Agreement.

 

RECITALS:

 

WHEREAS, pursuant
to the Agreement, Walgreens provides services related to the home administration of the pharmaceutical product known as Kalbitor;
and,

 

WHEREAS, the parties
desire to modify certain terms of the Agreement as set forth herein;

 

NOW, THEREFORE, for
and in consideration of the mutual covenants and promises set forth herein and in the Agreement, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, Walgreens and Dyax hereby agree to amend the Agreement as follows:

 

AGREEMENT:

 

		1.	Modification of Commitments. Subsection (b)(i) of Section 3.2 (Walgreens Commitments)
is hereby deleted in its entirety and replaced with the phrase “Intentionally Deleted”.

 

		2.	Deletion of Rebate. Section 3.21 (“Rebate”) and the corresponding Exhibit
3.21 are hereby deleted in their entirety.

 

		3.	2015 Renewal Term. The Renewal Term commencing January 1, 2015, shall run for a two-year
period, with such Renewal Term to expire on December 31, 2016. Each Renewal Term thereafter shall be for one-year periods as set
forth in Section 8.1(a) of the Agreement.

 

    	Page 1 of 2

    	 

    

 

		4.	DX-2930 Distribution Rights. DX-2930 is an investigational product candidate being
developed by Dyax for the prevention of HAE attacks. If DX-2930 is approved by the FDA and offered by Dyax, and provided Walgreens
can meet the requirements being imposed by Dyax on all pharmacy network providers, then Dyax agrees to negotiate the terms for
the purchase and dispense by Walgreens of said product in good faith, with the terms offered by Dyax reasonably consistent with
terms offered by Dyax to any other party with respect to the FDA-approved version(s) of DX-2930. Notwithstanding anything to the
contrary set forth in the Agreement, this Section 3 (DX-2930 Distribution Rights) shall survive the expiration or early termination
of the Agreement, except in the event that Dyax terminates the Agreement pursuant to Section 8.1(b) [Termination for Material Breach]
or Section 8.1(c) [Termination for Insolvency], in which case this Section 3 shall not survive such termination.

 

		5.	Ratification of the Agreement. The parties hereby ratify the terms and conditions
of the Agreement, as amended herein.

 

IN WITNESS WHEREOF,
Walgreens and Dyax, through their respective duly authorized and acting representatives, have executed and delivered this Amendment
to be effective as of the date first set forth above.

 

	DYAX CORP.	 	WALGREEN INFUSION SERVICES, INC.
	 	 	 
	By: /s/Kathleen DiRamio	 	By: /s/Lori Zsitek
	 	 	 
	Name: Kathleen DiRamio	 	Name: Lori Zsitek
	 	 	 
	Title: Associate Director, Nursing Services	 	Title: VP, Operations

 

    	Page 2 of 2Exhibit 10.8(e)

 

FOURTH AMENDMENT TO

THE AGREEMENT FOR SERVICES RELATED TO KALBITOR®

BY AND BETWEEN

DYAX CORP.

AND

WALGREENS INFUSION SERVICES, INC.

 

THIS FOURTH AMENDMENT
TO THE AGREEMENT FOR SERVICES RELATED TO KALBITOR® (the “Fourth Amendment”) is made and entered
into as of the 30th day of December 2014 (the “Fourth Amendment Effective Date”), by and between DYAX CORP.,
a Delaware corporation (“Dyax”), and WALGREENS INFUSION SERVICES, INC., a Delaware corporation (“Walgreens”),
to amend that certain Agreement For Services Related to Kalbitor, effective as of September 1, 2011, entered into by and between
Dyax and Walgreens, as modified by that certain First Amendment dated as of August 31, 2012, that certain Second Amendment dated
as of September 30, 2013, and that certain Third Amendment dated as of July 1,2014 (collectively, the “Agreement”).
Capitalized terms used herein which are not defined shall have the meanings given to them in the Agreement.

 

RECITALS:

 

WHEREAS, pursuant
to the Agreement, Walgreens provides services related to the home administration of the pharmaceutical product known as Kalbitor;
and,

 

WHEREAS, the parties
desire to modify certain services and associated fees provided by Walgreens, in accordance with the terms and conditions set forth
herein;

 

NOW, THEREFORE, for
and in consideration of the mutual covenants and promises set forth herein and in the Agreement, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, Walgreens and Dyax hereby agree to amend the Agreement as follows:

 

AGREEMENT:

 

		1.	The Agreement is hereby amended by adding the following term to Section 2 (DEFINITIONS, CONSTRUCTION):

 

““Service Provider Generated
Patient Referral” shall mean a referral, appropriate form or other written notification setting forth a Patient’s
desire to obtain infusion services that has been principally generated through the efforts of the Service Provider, with any Referral
routed through Service Provider or that includes a notation thereon that refers to Service Provider to be considered a Referral
principally generated through the efforts of Service Provider. References made to “Patient Referral” throughout this
Agreement shall also include “Service Provider Generated Referral.””

 

    	Page 1 of 3

    	 

    

  

		2.	Section 3.7 (a) (First Right to Provide Services) is hereby deleted in its entirety and replaced
with the following:

 

“Dyax agrees that Service Provider
shall be provided with the first right to provide Services in respect of any Patient that is the subject of a Service Provider
Generated Patient Referral. Further, Dyax agrees that all other referrals shall be allocated in a manner that treats Service Provider
no less favorably than any other in-network pharmacy or provider of infusion services.”

 

		3.	The following is hereby added to the Agreement as a new Section 5.6:

 

“5.6      Data Utilization.
Notwithstanding anything to the contrary set forth in the Agreement, all data collected by Service Provider in the performance
of the Data Services: (i) is and shall remain the property of Service Provider; (ii) constitutes the Confidential Information of
Service Provider pursuant to Section 2 and Section 12 of this Agreement, subject to the use and disclosure rights expressly granted
to Dyax in the Agreement (it being the intention of the Parties to not alter or diminish such rights by the terms of this Section
5.6); and (iii) may be used and disclosed by Service Provider in any manner and for any purpose permitted under Applicable Law.”

 

		4.	The Agreement is hereby amended by deleting the first two sentences of Section B(1) of Schedule
A (Description of Services).

 

		5.	The Agreement is hereby amended by adding the following new paragraph to Section B “Initial
Intake” of Schedule A (Description of Services):

 

“Service Provider will forward
Service Provider Generated Patient Referral to Kalbitor Access, which is the centralized customer support center operated or engaged
by Dyax provided the Service Provider has a signed HIPAA Patient Authorization Form on file. If no HIPAA Authorization Form is
on file, Service Provider will, in accordance with Service Provider’s standard operating procedures, advise the Patient of
any relevant patient services available through Kalbitor Access. Service Provider shall, promptly following its receipt of a Service
Provider Generated Patient Referral, obtain from the Patient’s physician a treatment order sheet confirming the physician’s
orders for Infusion Services and the dispensing of an anaphylaxis kit.”

 

		6.	The parties hereby ratify the terms and conditions of the Agreement, as amended herein.

 

[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK;

SIGNATURE PAGE FOLLOWS]

 

    	Page 2 of 3

    	 

    

 

IN WITNESS WHEREOF,
Walgreens and Dyax, through their respective duly authorized and acting representatives, have executed and delivered this Fourth
Amendment to be effective as of the Fourth Amendment Effective Date.

 

	DYAX CORP.	 	WALGREEN INFUSION SERVICES, INC.
	 	 	 
	By: /s/Kathleen DiRamio	 	By: /s/Lori Zsitek
	 	 	 
	Name: Kathleen DiRamio	 	Name: Lori Zsitek
	 	 	 
	Title: Associate Director, Nursing Services	 	Title: VP, Operations

 

    	Page 3 of 3Exhibit 10.12

 

Execution Version

 

AMENDED AND RESTATED

EXECUTIVE RETENTION AGREEMENT

 

This AMENDED AND RESTATED
EXECUTIVE RETENTION AGREEMENT ("Agreement"), dated effective as of December 23, 2014 (the "Effective Date"),
is entered into between Dyax Corp., a Delaware corporation with offices at 55 Network Drive, Burlington, Massachusetts 01803 ("Dyax"
or the "Company") and Gustav Christensen (the "Executive") amends and restates that certain Executive
Retention Agreement (the “Existing Retention Agreement”) between the Company and Executive dated December 22,
2010 (the “Original Effective Date”).

 

WHEREAS, the Executive
is an executive officer and key member of the Dyax management team.

 

WHEREAS, Dyax believes
that it is in the best interests of the Company and of its stockholders to provide for the continuity and retention of its executive
officers, including the Executive.

 

WHEREAS, the Existing Retention
Agreement is being amended so that it includes each type of Award that may be subject to the terms hereof.

 

NOW, THEREFORE, as an inducement
for and in consideration of the Executive remaining in the employ of the Company and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Company and the Executive agree that the Executive shall receive
the severance payments set forth in this Agreement in the event the Executive's employment with the Company is terminated under
the circumstances described below.

 

1.           Definitions.

 

Capitalized terms that
are not defined herein shall have the meanings set forth in Exhibit A attached hereto.

 

2.           EMPLOYMENT
STATUS.

 

The Executive acknowledges
that this Agreement does not constitute a contract of employment or impose on the Company any obligation to retain the Executive
as an employee and that this Agreement does not prevent the Company or the Executive from terminating his or her employment at
any time, for any reason, before or after a Change in Control.

 

3.           Term
of AgrEEMENT. 

 

3.1         Term.
This Agreement, and all rights and obligations of the parties hereunder, shall take effect upon the Effective Date and shall continue
through the third anniversary of the Original Effective Date (the "Term"); provided, however, that that the Term
shall be extended as follows:

 

(a)          Annual
Extension. Commencing on third anniversary of the Original Effective Date and each anniversary of the Original Effective Date
thereafter (each hereinafter referred to as a "Renewal Date"), the Term shall be automatically extended for one
additional year so as to terminate one year after such Renewal Date, unless at least one year prior to such Renewal Date, the Company
shall have given the Executive written notice that the Term will not be extended.

 

    	 

    	 

    

 

(b)          Extension
Following Change in Control or Termination of Employment. If a Change in Control shall have occurred during the Term, then
the Term shall automatically be extended for an additional year until one year after the closing of the transaction giving rise
to the Change in Control. If either a termination of employment covered by Section 5.1 or a Change in Control covered by Section
5.2 shall have occurred during the Term, then the Term shall be extended through the Severance Period (or to such later date by
which the Company has fulfilled all of its obligations under Section 5).

 

4.           Notice of Termination of Employment. 

 

4.1          Notice
of Termination. Any termination of the Executive's employment by the Company, or by the Executive prior to the first anniversary
of a Change in Control (other than due to the death or Disability of the Executive) shall be communicated by a written notice to
the other party hereto (the "Notice of Termination"), given in accordance with Section 8.2. Any Notice of Termination
shall: (i) indicate (in the case of a termination by the Company) whether such termination is for Cause and (in the case of a termination
by the Executive within one (1) year following a Change in Control) whether such termination is for Good Reason, (ii) to the extent
applicable, set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive's
employment for Cause or for Good Reason, and (iii) specify the Termination Date.

 

4.2          Timing
of Notice.

 

(a)          Any
Notice of Termination for Cause given by the Company must be given within ninety (90) days of the initial existence of the occurrence
or condition that constitutes Cause.

 

(b)          Any
Notice of Termination for Good Reason given by the Executive must be given within thirty (30) days of the initial existence of
the occurrence or condition that constitutes Good Reason. If the condition is capable of being corrected, the Company shall have
thirty (30) days during which it may remedy the condition (the "Cure Period"). Notwithstanding the occurrence
of any such event or circumstance, such occurrence shall not be deemed to constitute Good Reason if such event or circumstance
has been fully corrected within the Cure Period. If the condition is not corrected, the Executive must leave employment within
ninety (90) days after the Company fails to cure the condition giving rise to the Executive's claim for Good Reason during the
Cure Period.

 

5.           Benefits
to Executive. 

 

5.1         Termination
Prior to Change in Control. If, prior to a Change in Control (including a situation in which a Change in Control never occurs),
the Company terminates the Executive's employment other than for Cause, Disability or death, then notwithstanding anything to the
contrary contained in any prior agreement, the Executive shall be entitled to benefits described in subsections (a) through (d)
below, the distribution of which shall be subject to the provisions of Sections 5.4, 5.5 and 5.8.

 

(a)          The
Company shall pay to the Executive on the Termination Date, in a lump sum, in cash (less applicable withholdings), (i) all base
salary and accrued vacation pay earned by the Executive through the Termination Date (the "Accrued Obligations");
and (ii) the Executive's actual incentive bonus earned, based on the achievement of corporate and individual goals through the
date of Executive's termination; provided however, that if any portion of the Executive's actual incentive bonus earned is not
determinable as of the date of termination, Executive shall receive for that portion an amount equal to the pro rated portion of
Executive's annual target bonus, based upon the number of days during such calendar year that the Executive had been employed prior
to the Termination Date.

 

    	-2-

    	 

    

 

(b)          During
the Severance Period, the Company shall continue to pay to the Executive, in accordance with the Company's regular payroll practices,
the Executive's base salary.

 

(c)          During
the Severance Period, the Company shall continue to provide coverage to the Executive in accordance with and subject to the terms
of the applicable welfare benefit plans of the Company in effect on the Termination Date; provided, however, that if the Executive
becomes reemployed with another employer and is eligible to receive a particular type of benefits (e.g., health insurance benefits)
from such employer, then the Company shall no longer be required to provide those particular benefits to the Executive.

 

(d)          With
respect to any Awards granted to the Executive by the Company prior to the Termination Date:

 

(i)           any
such Awards that are subject to time-based vesting and are unvested as of the Termination Date shall continue to vest through the
Severance Period;

 

(ii)          all
Awards that have an exercise period, including without limitation stock options, shall remain exercisable by the Executive for
ninety (90) days following the conclusion of the Severance Period but in no event beyond the maximum term of any such Award; and

(iii)         any
performance-based Awards shall have such terms as are set forth in the grant agreement applicable thereto

 

The Executive acknowledges and agrees
that the provisions of this Section 5.1(d) may cause all stock options which had previously been qualified as Incentive Stock Options
under Section 422 of the Internal Revenue Code of 1986, as amended (the "Code", which term shall include applicable
Treasury Regulations) to become non-qualified options and lose, irrevocably, any tax-advantaged treatment previously available,
except to the extent that the effectiveness of such provisions would permit such options to qualify as a grant of new Incentive
Stock Options under Section 422 (in which case the exception shall be applied by the Company to the Options with the lowest exercise
prices as Incentive Stock Options up to the $100,000 limit in Section 422).

 

5.2          Termination
Following Change in Control. If the Company terminates the Executive's employment other than for Cause, Disability or death
within twelve (12) months following a Change in Control, or if the Executive terminates his or her employment for Good Reason within
twelve (12) months following a Change in Control, then notwithstanding anything to the contrary contained in any prior agreement,
the Executive shall be entitled to benefits described in subsections (a) through (d) below, the distribution of which shall be
subject to the provisions of Sections 5.4, 5.5 and 5.8:

 

(a)          The
Company shall pay to the Executive on the Termination Date, in a lump sum, in cash (less applicable withholdings):

 

(i)           the
Accrued Obligations;

 

(ii)          the
Executive's annual target bonus for the calendar year in which the termination occurred, pro-rated based upon the number of days
during such calendar year that the Executive had been employed prior to the Termination Date; and

 

    	-3-

    	 

    

 

(iii)         an
amount equal to one hundred fifty percent (150%) of the Executive's annual base salary and target bonus.

 

(b)          During
the Severance Period, the Company shall continue to provide coverage to the Executive in accordance with and subject to the terms
of the applicable welfare benefit plans of the Company in effect on the Termination Date; provided, however, that if the Executive
becomes reemployed with another employer and is eligible to receive a particular type of benefits (e.g., health insurance benefits)
from such employer, then the Company shall no longer be required to provide those particular benefits to the Executive; and

 

(c)          With
respect to any Awards granted to the Executive by the Company prior to the Termination Date:

 

(i)           any
Awards that are subject to time-based vesting and unvested as of the Termination Date shall become immediately exercisable effective
as of the Termination Date; and

 

(ii)          all
Awards that have an exercise period, including without limitation stock options, shall remain exercisable by the Executive for
ninety (90) days following the conclusion of the Severance Period but in no event beyond the maximum term of any such Award; and

(iii)         any
performance-based Awards shall have such terms as are set forth in the grant agreement applicable thereto.

 

The Executive acknowledges and agrees
that the provisions of this Section 5.1(d) may cause any stock options which had previously been qualified as Incentive Stock Options
under Section 422 of the Code to become non-qualified options and lose, irrevocably, any tax-advantaged treatment previously available.

 

5.3          Termination
for Cause, Disability or Death. If the Company terminates the Executive's employment for Cause, Disability or death, whether
prior to or following a Change in Control, then the Company shall pay the Executive (or his or her estate, if applicable), in a
lump sum in cash on the Termination Date, the Accrued Obligations and (ii) to the extent not previously paid or provided, timely
pay or provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible
to receive following the Executive's termination of employment under any plan, program, policy, practice, contract or agreement
of the Company and its subsidiaries (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits"),
the distribution of which shall be subject to the provisions of Section 5.8.

 

5.4          Section
280G Provisions.

 

(a)          If
the Company undergoes a Change in Ownership or Control (as defined below) and any portion of the Contingent Compensation Payments
(as defined below) payable to the Executive hereunder would constitute Excess Parachute Payments (as defined below), then,
subject to Section 5.4(b) below, the Company shall reduce the Contingent Compensation Payments (as defined below) to the extent
necessary to eliminate such Excess Parachute Payments. For purposes of this Section 5.4, the Contingent Compensation Payments so
eliminated shall be referred to as the "Eliminated Payments" and the aggregate amount (determined in accordance
with Treasury Regulation Section 1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated
shall be referred to as the "Eliminated Amount."

 

    	-4-

    	 

    

 

(b)          Notwithstanding
anything to the contrary contained in Section 5.4(a), no such reduction in Contingent Compensation Payments shall be made if (i)
the Eliminated Amount exceeds (ii) the amount of the excise tax imposed on the Executive by Section 4999 of the Code with respect
to the Excess Parachute Payments. The override of such reduction in Contingent Compensation Payments pursuant to this Section 5.4(b)
shall be referred to as a "Section 5.4(b) Override."

 

(c)          For
purposes of this Section 5.4 the following terms shall have the following respective meanings:

 

(i)          "Change
in Ownership or Control" shall mean a change in the ownership or effective control of the Company, or in the ownership
of a substantial portion of the assets of the Company, determined in accordance with Section 280G(b)(2) of the Code.

 

(ii)         "Contingent
Compensation Payment" shall mean any payment (or benefit) in the nature of compensation that is made or made available
(under this Agreement or otherwise) to a "disqualified individual" (as defined in Section 280G(c) of the Code) and that
is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company.

 

(iii)        "Excess
Parachute Payment" shall mean a payment described in Section 280G(b)(1) of the Code (calculated based on the applicable
federal rate in effect on the Original Effective Date with respect to stock options).

 

(d)          Any
payments or other benefits otherwise due to the Executive following a Change in Ownership or Control that could reasonably be characterized
(as determined by the Company) as Contingent Compensation Payments (the "Potential Payments") shall not be made
until the dates provided for in this Section 5.4(d).

 

(i)          In
the event that the Company undergoes a Change in Ownership or Control, and the Executive becomes entitled to receive Contingent
Compensation Payments relating to such Change in Ownership or Control, the Company shall (A) determine at such time or times as
may be necessary to comply with the requirements under Section 280G of the Code whether such Contingent Compensation Payments constitute
in whole or in part Excess Parachute Payments and (B) in the event the Company determines that such Contingent Compensation Payments
constitute in whole or in part Excess Parachute Payments, notify the Executive (within 30 days after each such determination and
with reasonable detail regarding the basis for its determinations) of the following: (1) which Potential Payments constitute Contingent
Compensation Payments, (2) the Eliminated Amount, and (3) whether the Section 5.4(b) Override is applicable.

 

    	-5-

    	 

    

 

(ii)         Within
thirty (30) days after delivery of such notice to the Executive, the Executive shall deliver a response to the Company (the "Executive
Response") stating either (A) that the Executive agrees with the Company's determination pursuant to the preceding sentence,
or (B) that the Executive disagrees with such determination, in which case the Executive shall set forth (1) which Potential Payments
should be characterized as Contingent Compensation Payments, (2) the Eliminated Amount, or (3) whether the Section 5.4(b) Override
is applicable.

 

(iii)        If
and to the extent that any Contingent Compensation Payments are required to be treated as Eliminated Payments pursuant to this
Section 5.4 and the Section 5.4(b) Override is not applicable, then the Payments shall be reduced or eliminated, as determined
by the Company, in the following order: (A) any cash payments, (B) any vesting of equity awards, (C) any taxable benefits, and
(D) any nontaxable benefits, in each case beginning with payments or benefits that are to be paid the farthest in time from the
date that triggers the applicability of the excise tax, to the extent necessary to maximize the Eliminated Payments.

 

(iv)        If
the Executive fails to deliver an Executive Response on or before the required date, the Company's initial determinations shall
be final, and the Company shall make the Potential Payments (other than the Eliminated Payments) to the Executive within ten (10)
business days following the due date for delivery to the Company of the Executive Response (except for any Potential Payments which
are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).

 

(v)         If
the Executive states in the Executive Response that he or she agrees with the Company's determinations, the Company's initial determinations
shall be final, the Contingent Compensation Payments that shall be treated as Eliminated Payments shall be as set forth in the
Executive Response, and the Company shall make the Potential Payments (other than the Eliminated Payments) to the Executive within
ten (10) business days following delivery to the Company of the Executive Response (except for any Potential Payments which are
not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).

 

(vi)        If
the Executive states in the Executive Response that he or she disagrees with the Company's determinations, then, for a period of
thirty (30) days following delivery of the Executive Response, the Executive and the Company shall use good faith efforts to resolve
such dispute. If such dispute is not resolved within such thirty (30) day period, such dispute shall be settled exclusively by
arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect. Judgment
may be entered on the arbitrator's award in any court having jurisdiction. The Company shall, within ten (10) business days following
delivery to the Company of the Executive Response, make to the Executive those Potential Payments as to which there is no dispute
between the Company and the Executive regarding whether they should be made (except for any such Potential Payments which are not
due to be made until after such date, which Potential Payments shall be made on the date on which they are due). The balance of
the Potential Payments (other than Eliminated Payments) shall be made within ten (10) business days following the resolution of
such dispute.

 

    	-6-

    	 

    

 

(vii)       Subject
to the limitations contained in Sections 5.4(a) and (b) hereof, the amount of any payments to be made to the Executive following
the resolution of such dispute shall be increased by amount of the accrued interest thereon computed at the prime rate announced
from time to time by Bank of America, compounded monthly from the date that such payments originally were due.

 

(viii)      In
the event the Company is required to perform a redetermination in accordance with Treas. Reg. 1.280G-1 Q/A-33(b) with respect to
any Contingent Compensation Payments, this Section 5.4(d) shall apply with respect to such redetermination and the parties shall
make such adjustments as may be necessary as a result of such redetermination including, if appropriate, the payment by the Company
of Contingent Compensation Payments previously treated as Eliminated Payments if the Section 5.4(b) Override applies as a result
of such redetermination.

 

(e)          The
provisions of this Section 5.4 are intended to apply to any and all payments or benefits available to the Executive under this
Agreement or any other agreement or plan of the Company under which the Executive receives Contingent Compensation Payments.

 

5.5           Release.
The obligation of the Company to make the payments and provide the benefits to the Executive under Section 5.1, 5.2 or 5.3 is conditioned
upon the Executive signing a release of claims in the form attached hereto as Exhibit B, or such other form as may be agreed
to by the Company and the Executive (the "Employee Release"), within twenty-one (21) days (the "Release
Period") following the Termination Date and upon the Executive not revoking the Employee Release in a timely manner thereafter.
Provided that the Employee Release has become binding, the payments to the Executive under Section 5.1 or 5.2 shall be payable
or shall commence on the 30th day following the Termination Date. Notwithstanding the foregoing, the provisions of benefits under
Section 5.1(c) and 5.2(c) shall continue during the Release Period and any applicable revocation period.

 

5.6           Exclusive
Severance Benefits. The making of the payments and the provision of the benefits by the Company to the Executive under Section
5.1, 5.2 or 5.3 shall constitute the entire obligation of the Company to the Executive as a result of the termination of his or
her employment under the circumstances set forth in such Sections, and the Executive shall not be entitled to additional payments
or benefits under any other plan, program, policy, practice, contract or agreement of the Company or its subsidiaries.

 

5.7           Mitigation.
The Executive shall not be required to mitigate the amount of any payment or benefits provided for in Section 5.1, 5.2 or 5.3 by
seeking other employment or otherwise. Further, except as provided in Section 5.1(c) and 5.2(c), the amount of any payment or benefits
provided for in Section 5.1, 5.2 or 5.3 shall not be reduced by any compensation earned or benefits received by the Executive as
a result of employment by another employer.

 

5.8           Section
409A. A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing
for the payment of any amounts or benefits that is considered deferred compensation upon or following a termination of employment
unless such termination of employment is also a "separation from service" within the meaning of Code Section 409A. If
the Executive is a "specified employee" on the date of termination within the meaning of that term under Code Section
409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered deferred compensation under Code
Section 409A payable on account of a "separation from service," such payment or benefit shall be made or provided at
the date which is the earlier of (i) the expiration of the six (6) month period measured from the date of the Executive's "separation
from service", and (ii) the date of the Executive's death (the "Delay Period"). Upon the expiration of the
Delay Period, all payments and benefits delayed pursuant to this provision shall be paid or reimbursed to the Executive in a lump
sum in cash.

 

    	-7-

    	 

    

 

5.9          Potential
Recovery of Incentive Compensation. Notwithstanding any other provision of this Agreement or the Certificate of Incorporation
or by-laws of the Company (including for this purpose any provision for indemnification), any compensation paid to the Executive
pursuant to this Agreement or in accordance with its terms shall be subject to any policy or arrangement regarding recovery of
incentive-based compensation (which may include stock options awarded as compensation and may exclude indemnification of the Executive
for any such recovery) hereafter adopted by the Board of Directors of the Company in order to comply with (i) Section
954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or any law of similar effect for recovery of
incentive-based compensation previously paid, and (ii) any regulations promulgated pursuant to any such law. 

 

6.           ADDITIONAL
COVENANTS.

 

6.1          Non-Competition.
During the Restricted Period, the Executive shall not, without the Company's prior written consent, directly or indirectly, as
principal, employee, consultant, partner or stockholder of, or in any capacity with, any business enterprise (other than as a holder
of not more than 1% of the combined voting power of the outstanding stock of a publicly held company):

 

(a)          engage
in the research, development, production, marketing, or sale of a product that competes (or, upon commercialization, will compete)
with any product that was marketed or sold by the Company prior to the termination of the Executive's employment and on which the
Executive worked or about which the Executive acquired Confidential Information;

 

(b)          engage
in the research, development, production, marketing, or sale of a product that competes (or, upon commercialization, will compete)
with any product of the Company that had entered into a Phase 2 clinical trial prior to the termination of the Executive's employment
and on which the Executive worked or about which the Executive acquired Confidential Information; or

 

(c)          engage
in the research, development, design or commercialization of any display technology which is licensed or sold (or marketed for
license or sale) in a manner that competes with the Company's phage display technology licensing and funded research program.

 

6.2          Non-Solicitation.
During the Restricted Period, the Executive shall not, without the Company's prior written consent, directly or indirectly, as
principal, employee, consultant, partner or stockholder of, or in any capacity with, any business enterprise (other than as a holder
of not more than 1% of the combined voting power of the outstanding stock of a publicly held company): (i) solicit, take away or
hire any employees or exclusive consultants of the Company; (ii) solicit or divert any of the business being conducted by the Company;
(iii) solicit, divert or accept any business that is being actively pursued by the Company with any customer or partner; or (iv)
divert investors or potential investors from the Company.

 

6.3          Non-Disparagement.
During the Term of this Agreement and at all times thereafter, the Executive shall not make any disparaging remarks to any third
party concerning the Company or any of its officers, directors, agents, employees, successors and assigns which might damage or
adversely affect their respective reputations, goodwill, or businesses.

 

    	-8-

    	 

    

 

7.           Settlement
of Disputes; Arbitration. 

 

All claims by the Executive
for benefits under this Agreement shall be directed to the Board and shall be in writing. Any denial by the Board of a claim for
benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the reasons for the denial and
the provisions of this Agreement relied upon. Any further dispute or controversy arising under or in connection with this Agreement
shall be settled exclusively by arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration
Association then in effect. Judgment may be entered on the arbitrator's award in any court having jurisdiction.

 

8.           Miscellaneous.

 

8.1           Successors.
This Agreement shall be binding upon the Company and its successors and assigns. This Agreement shall inure to the benefit of and
be enforceable by the Executive's personal or legal representatives, executors, administrators, successors, heirs, distributees,
devisees and legatees. If the Executive should die while any amount would still be payable to the Executive or his or her family
hereunder if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance
with the terms of this Agreement to the executors, personal representatives or administrators of the Executive's estate.

 

8.2           Notice.
All notices, instructions and other communications given hereunder or in connection herewith shall be in writing. Any such notice,
instruction or communication shall be sent either (i) by registered or certified mail, return receipt requested, postage prepaid,
or (ii) prepaid via a reputable nationwide overnight courier service, in each case addressed as follows:

 

	If to the Company, to: 	 	
        Dyax Corp.

        55 Network Drive

        Burlington, Massachusetts 01803

        Attention: Director of Human Resources

        Attention: Corporate Counsel

 

	If to the Executive, to:	 	
        Gustav Christensen

        3 Idlewilde Road

        Lexington, MA 02421

 

or to such other address as either the Company
or the Executive may have furnished to the other in writing in accordance herewith). Any such notice, instruction or communication
shall be deemed to have been delivered five business days after it is sent by registered or certified mail, return receipt requested,
postage prepaid, or one business day after it is sent via a reputable nationwide overnight courier service. Either party may give
any notice, instruction or other communication hereunder using any other means, but no such notice, instruction or other communication
shall be deemed to have been duly delivered unless and until it actually is received by the party for whom it is intended.

 

8.3           Employment
by Subsidiary. For purposes of this Agreement, the Executive's employment with the Company shall not be deemed to have terminated
solely as a result of the Executive continuing to be employed by a wholly-owned subsidiary of the Company.

 

    	-9-

    	 

    

 

8.4           Executive's
Cooperation. During the Term and thereafter, in the latter case subject to the Company's payment of the Executive's reasonable
out-of-pocket expenses that have been approved in advance, the Executive shall, at reasonable times and subject to the Executive's
other obligations, reasonably cooperate with the Company and its subsidiaries in any internal investigation, any administrative,
regulatory or judicial proceeding or any dispute with a third person as reasonably requested by the Company or any of its subsidiaries
(including the Executive being available to the Company and its subsidiaries upon reasonable notice for interviews and factual
investigations, appearing at the Company's or any of its subsidiaries' request to give testimony without requiring service of a
subpoena or other legal process, volunteering to the Company and its subsidiaries all pertinent information and turning over to
the Company and its subsidiaries all relevant documents which are or may come into the Executive's possession with respect to which
the Executive does not owe a countervailing duty of confidentiality or nonuse, all at times and on schedules that are reasonably
consistent with the Executive's other permitted activities and commitments).

 

8.5           Severability.
The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other
provision of this Agreement, which shall remain in full force and effect.

 

8.6           Governing
Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the internal laws of
the Commonwealth of Massachusetts, without regard to conflicts of law principles.

 

8.7           Waivers.
No waiver by the Executive at any time of any breach of, or compliance with, any provision of this Agreement to be performed by
the Company shall be deemed a waiver of that or any other provision at any subsequent time.

 

8.8           Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed to be an original but both of which together shall
constitute one and the same instrument.

 

8.9           Tax
Withholding. Any payments provided for hereunder shall be paid net of any applicable tax withholding required under federal,
state or local law.

 

8.10         Entire
Agreement. This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained
herein and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether
oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein;
and any prior agreement of the parties hereto in respect of the subject matter contained herein is hereby terminated and cancelled,
including without limitation the Existing Employment Agreement and that certain Employment Letter Agreement between the Company
and the Executive, dated as of April 26, 2007. Notwithstanding the foregoing, the Company's Employee Confidentiality Agreement
as in effect from time to time between the Company and the Executive, shall not be superseded by or modified by the terms of this
Agreement and shall remain in full force and effect.

 

8.11         Amendments.
This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.

 

8.12         Executive's
Acknowledgements. The Executive acknowledges that he or she: (a) has read this Agreement; (b) has been represented in the preparation,
negotiation, and execution of this Agreement by legal counsel of the Executive's own choice or has voluntarily declined to seek
such counsel; and (c) understands the terms and consequences of this Agreement.

 

    	-10-

    	 

    

 

IN WITNESS WHEREOF, the
parties hereto have executed this Executive Retention Agreement as an instrument under seal of the date first set forth above.

 

	Dyax Corp.	 	EXECUTIVE
	 	 	 	 
	By:	/s/ Joan Nickerson	 	/s/ Gustav Christensen
	 	Name: Joan Nickerson	 	Gustav Christensen
	 	Title: Sr. Director, HR	 	 

 

 

    	-11-

    	 

    

 

Exhibit
A

DEFINED
TERMS

 

		Award	“Award” shall mean any option, stock appreciation right, performance share, restricted
stock, stock unit or other stock-based award awarded under the Company’s Amended and Restated 1995 Equity Incentive Plan,
as amended from time to time, or any successor plan.

 

		Board	"Board" shall mean the Board of Directors of the Company

 

		Change in
                          Control	"Change
in Control" shall mean an event or occurrence set forth in any one or more of subsections (a) through (d) below:

 

(a)          any
"person," as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the "Exchange
Act") (other than the Company, any trustee or other fiduciary holding securities under an employee benefit plan of the Company,
or any corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportion as their
ownership of stock in the Company) is or becomes the "beneficial owner" (as defined in Rule 13d-3 under the Exchange
Act), directly or indirectly (other than as a result of acquisitions of such securities from the Company), of securities of the
Company representing fifty percent (50%) or more of the combined voting power of the Company's then outstanding securities entitled
to vote generally in the election of directors;

 

(b)          individuals
who, as of the date hereof, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least
a majority of the Board, provided that any person becoming a director subsequent to the date hereof whose election, or nomination
for election by the Company's stockholders, was approved by a vote of at least a majority of the directors then comprising the
Incumbent Board (other than an election or nomination of an individual whose initial assumption of office is in connection with
an actual or threatened election contest relating to the election of directors of the Company) shall be, for purposes of this Agreement,
considered to be a member of the Incumbent Board;

 

(c)          the
consummation of a merger, share exchange or consolidation of the Company or any subsidiary of the Company with any other entity
(each a "Business Combination"), other than (A) a Business Combination that would result in the voting securities of
the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted
into voting securities of another entity) beneficial ownership, directly or indirectly, of a majority of the combined voting power
of the Company or the surviving entity (including any person that, as a result of such transaction, owns all or substantially all
of the Company's assets either directly or through one or more subsidiaries) outstanding immediately after such Business Combination
or (B) a merger, share exchange or consolidation effected to implement a recapitalization of the Company (or similar transaction)
in which no "person" (as defined above) is or becomes the beneficial owner of fifty percent (50%) or more of the combined
voting power of the Company's then outstanding securities; or

 

(d)          the
stockholders of the Company approve (A) a plan of complete liquidation of the Company; or (B) an agreement for the sale or disposition
by the Company of all or substantially all of the Company's assets but excluding a sale or spin-off of a product line, business
unit or line of business of the Company if the remaining business is significant as determined by the Company's board of directors
in its sole discretion.

 

Exhibit A

 

    	 

    	 

    

 

		Cause	"Cause" shall mean:

 

(a)          the
willful and continued failure by the Executive to perform his or her duties with the Company (other than any such failure resulting
from incapacity due to physical or mental illness or any failure resulting from the Executive's termination of his or her employment
with the Company for Good Reason), as determined by the Company; or

 

(b)          any
act of material misconduct (including insubordination) or the commission of any act of dishonesty or moral turpitude in connection
with the Executive's employment, as determined by the Company; or

 

(a)          the
Executive's conviction or plea of nolo contendere of a felony or a crime involving moral turpitude.

 

		Disability	"Disability" shall mean the Executive shall have been deemed "disabled" by
the institution appointed by the Company to administer the Company's Long-Term Disability Plan (or successor plan).

 

		Good Reason	"Good Reason" shall mean the occurrence, without the Executive's written consent, of any of the
following events or circumstances:

 

(a)          The
material diminution of the Executive's duties with the Company from that immediately prior to the Change in Control; or

 

(b)          A
material reduction by the Company (other than across-the-board reductions applicable to all similarly situated employees of the
Company and the acquiror of the Company), in the Executive's base salary in effect immediately prior to the Change in Control;
or

 

(c)          Any
requirement by the Company that the location at which the Executive performs his or her principal duties for the Company be changed
to a new location that is more than fifty (50) miles from the location at which the Executive performs his or her principal duties
for the Company immediately prior to the Change in Control.

 

	Restricted Period	"Restricted Period" shall mean: (i) with respect to any termination that occurs under Section 5.1 or 5.2, the period of twenty-one (21) months immediately following the Termination Date; or (ii) with respect to any termination that occurs under Section 5.3, the period of twelve (12) months immediately following the Termination Date. 
	 	 
	Severance Period	"Severance Period" shall mean the period of eighteen (18) months immediately following the Termination Date. 
	 	 
	Termination Date	"Termination Date" shall mean the close of business on the date specified in the Notice of Termination (which date may not be less than fifteen (15) business days or more than one hundred twenty (120) days after the date of delivery of such Notice of Termination), in the case of a termination other than one due to the Executive's Disability or death, or the date of the Executive's Disability or death, as the case may be.

 

Exhibit A

 

    	 

    	 

    

 

EXHIBIT
B

RELEASE

 

In consideration of the
payment to me of the severance benefits pursuant to my Executive Severance Benefit Agreement with Dyax Corp. (the "Company")
dated ___________________, 2010 (the "Agreement"), I hereby agree as follows:

 

1.          I,
on behalf of myself and my representatives, agents, estate, heirs, successors and assigns, hereby irrevocably and unconditionally
release, remise and discharge the Company, its officers, directors, stockholders, affiliates (within the meaning of the Securities
Act of 1933), attorneys, agents and employees, and their respective predecessors, successors and assigns (collectively, the "Company
Releasees"), from any and all actions or causes of action, suits, claims, complaints, liabilities, contracts, torts, debts,
damages, controversies, rights and demands, whether existing or contingent, known or unknown, arising up to and through the date
of this Release out of my employment, or the termination of my employment, with the Company, including, but not limited to, all
employment discrimination claims under the Age Discrimination in Employment Act, 29 U.S.C. §621 et seq., Title VII of the
Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et
seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification Act ("WARN"),
29 U.S.C. § 2101 et seq., the Massachusetts Fair Employment Practices Act, M.G.L. c.151B, § 1 et seq., the Massachusetts
Civil Rights Act, M.G.L. c.12, §§ 11H and 11I, the Massachusetts Equal Rights Act, M.G.L. c.93, § 102 and M.G.L.
c.214, § 1C, the Massachusetts Labor and Industries Act, M.G.L. c.149, § 1 et seq., and the Massachusetts Privacy Act,
M.G.L. c.214, § 1B, all as amended, and all claims arising out of the Fair Credit Reporting Act, 15 U.S.C. § 1681 et
seq. and the Employee Retirement Income Security Act of 1974 ("ERISA"), 29 U.S.C. § 1001 et seq., all as
amended; and all claims to any non-vested ownership interest in the Company, contractual or otherwise, including, but not limited
to, claims to stock or stock options. Notwithstanding the foregoing, (a) nothing in this Release prevents me from filing, cooperating
with, or participating in any proceeding before the EEOC or a state Fair Employment Practices Agency (except that I acknowledge
that I may not recover any monetary benefits in connection with any such claim, charge or proceeding), (b) this Release does not
extend to any rights I have that arise after the date hereof under the Agreement and (c) this Release does not extend to any rights
I may have to indemnification as an officer or director of the Company under the provisions of the Company's By-laws or applicable
law.

 

2.          I
have been advised by the Company to consult with counsel before signing this Release, and have been given the opportunity to consult
with my own counsel prior to signing this Release.

 

3.          I
have been given up to twenty-one (21) days from the receipt of this Release to consider whether to execute this Release.

 

4.          I
have been advised that even after I sign this Release, I may revoke it within seven (7) days of the date of my signing by delivering
a signed revocation notice to the Company. Delivery by ordinary mail will effectively revoke my assent to this Release if it is
postmarked no later than seven days after I sign this Release.

 

5.          This
Release shall not become effective and in force until eight days after I sign, provided I have not timely revoked my acceptance.

 

6.          I
acknowledge and reaffirm my obligations under the Dyax Corp. Employee Confidentiality Agreement.

 

7.          No
representation, promise or inducement has been offered or made to induce me to enter into this Release, and I am competent to execute
this Release and accept full responsibility therefor.

 

	Signature:	 	 
	 	 	 
	Name:	 	 

 

Exhibit B

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]